Online Exclusives

Trials & Filings in Brief: Sept. 25, 2013

By Gil Roth | September 25, 2013

Acorda, Amarin, Bayer, Cardiome, Cornerstone, KemPharm, Merck Serono and Mylan

Phase II
Cornerstone begins trial for myelodysplastic syndrome . . . read more

Acorda enrolls for spinal injury trial . . . read more

Phase III
Merck Serono to conduct cancer immunotherapy trial . . . read more

Generics
Mylan sued over first-to-file challenge of Savella . . . read more

Outcomes
Amarin enrolls 6,000+ in REDUCE-IT CV trial . . . read more

Approvals
Cardiome gains Brinavess approval in Turkey . . . read more

Bioequivalence
KemPharm's abuse-resistant opioid shows equivalence to RLD . . . read more

Filings
Bayer receives orphan status for riociguat . . . read more
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research